What We Have Learned From Adjuvant Therapy for Resected EGFR-Mutant Non-Small-Cell Lung Cancer

J Clin Oncol. 2022 Jan 20;40(3):217-220. doi: 10.1200/JCO.21.02443. Epub 2021 Nov 18.

Authors

Si-Yang Liu¹, Jia-Tao Zhang¹, Yi-Long Wu¹

Affiliation

¹ Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine South China University of Technology, Guangzhou, Guangdong, P. R. China.

PMID: 34793259
DOI: 10.1200/JCO.21.02443

No abstract available

Publication types

Editorial
Comment

MeSH terms

Carcinoma, Non-Small-Cell Lung* / drug therapy
Carcinoma, Non-Small-Cell Lung* / genetics
Combined Modality Therapy
ErbB Receptors / genetics
Gefitinib
Humans
Lung Neoplasms* / drug therapy
Lung Neoplasms* / genetics

Substances

EGFR protein, human
ErbB Receptors
Gefitinib